AJA 001
Alternative Names: AJA-001Latest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator AJNA Australia
- Class Behavioural disorder therapies; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pervasive child development disorders
Most Recent Events
- 12 Dec 2024 Adverse event data from a phase I trial in Pervasive child development disorders released by Charlotte's Web
- 12 Dec 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a phase I trial in Pervasive child development disorders released by DeFloria
- 12 Dec 2024 AJNA Australia plans a phase II trial Pervasive child development disorders (In children, In adolescents, In adults) in second quarter of 2025